# OnCo record alk-fusion (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/alk-fusion/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "alk-fusion" ;
  schema:name "ALK fusion (ALK-positive)"@en ;
  schema:alternateName "ALK fusion"@en, "ALK rearrangement"@en, "ALK-positive"@en, "ALK+"@en, "EML4-ALK"@en, "EML4::ALK"@en, "ALK translocation"@en, "ALK gene rearrangement"@en ;
  schema:description "An ALK fusion, usually EML4::ALK, is a swapped piece of chromosome 2 that turns the ALK kinase on permanently in about 4 percent of lung adenocarcinomas. Seven ALK inhibitors are approved for it, including alectinib after surgery."@en ;
  schema:url <https://onco.cc/biomarkers/alk-fusion/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=004f93d7-a1cd-4b67-9207-31cdcb5c5976> ;
  onco:tag "biomarker", "fusion" ;
  onco:related <https://onco.cc/biomarkers/ros1-fusion/>, <https://onco.cc/biomarkers/ret-fusion/>, <https://onco.cc/biomarkers/ntrk-fusion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/kras-wild-type-pdac/> ;
  onco:drugs <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/brigatinib/>, <https://onco.cc/drugs/ceritinib/>, <https://onco.cc/drugs/ensartinib/>, <https://onco.cc/drugs/foundationone-cdx/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/fish/>, <https://onco.cc/terms/tki-term/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-singhi-alk-rearrangements-pancreatic-jnccn-2017/>, <https://onco.cc/key-papers/paper-philip-kras-wild-type-pancreatic-ccr-2022/>, <https://onco.cc/key-papers/paper-soda-eml4-alk-fusion-nature-2007/>, <https://onco.cc/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/>, <https://onco.cc/key-papers/paper-gainor-alk-resistance-mutations-cancer-discov-2016/>, <https://onco.cc/key-papers/paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019/>, <https://onco.cc/key-papers/paper-lindeman-lung-molecular-testing-guideline-jto-2018/> .